HKEX opportunity knocking

Jefferies’ Brinkman weighs in on the new HKEX biotech chapter

The rapid growth of biotech in the greater China region is something Jefferies does not intend to miss.

With the opening of a new biotech chapter on the Hong Kong Exchanges and Clearing Ltd. on April 30, the bank’s small team in China is now focused primarily on HKEX listings, according to investment banker Michael Brinkman.

He said Jefferies also is supporting the work with U.S. and European resources from all levels of its organization.

Brinkman, a managing director in the Global Healthcare Investment Banking Group, has nearly 25 years of experience advising and raising capital for U.S. biotechnology and specialty pharmaceuticals companies.

In March, he attended the annual China Healthcare Investment Conference (CHIC) for the first time and was impressed by the quality of the presenting companies.

He’s expecting HKEX’s new biotech chapter to start hot with a first wave of established players that will have little trouble clearing the exchange’s entry hurdles.

The HKEX chapter has listing criteria including a minimum market cap of HK$1.5 billion ($191.1 million) and a product candidate that has completed Phase I testing and can start Phase II or later trials without objection from regulators including FDA,

Read the full 1888 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers